Atlas Trials

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Clinical trial NCT06691984 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06691984
Sponsor
Amgen
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Metastatic Castration-resistant Prostate Cancer
Start date
2024-12-09
Primary completion
2029-01-02
Enrollment
707

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.